Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Single-arm, Prospective Phase II Clinical Study of the Efficacy and Safety of AK105 Combined With Anlotinib in the Treatment of Persistent, Recurrent, and Metastatic Cervical Cancer

NCT05137171 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.

NCT NCT05137171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05137171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Single-arm, Prospective Phase II Clinical Study of the Efficacy and Safety of AK105 Combined With Anlotinib in the Treatment of Persistent, Recurrent, and Metastatic Cervical Cancer
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2022
Completion date
September 1, 2024
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer